• Sensorion will host an SENS-601 Program Day on Sept. 22, 2026, starting 2:30 p.m. CET (8:30 a.m. ET).
• Event will outline the SENS-601 gene therapy program for GJB2-related hearing loss, including the HearConnex trial design and endpoints.
• Management will present alongside external speakers Christine Petit and Sharon Cushing, HearConnex coordinating investigator.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensorion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609180130BIZWIRE_USPR_____20260917_BW771874) on September 18, 2026, and is solely responsible for the information contained therein.